Arizona’s Prescription Drug Monitoring Program (PDMP)

The Arizona State Board of Pharmacy Controlled Substances Prescription Monitoring Program (PMP) grants access to prescribers and pharmacists so that they may review controlled substance dispensing information for patients.

What Arizona Health Practitioners and Pharmacists Need to Know

- Arizona Revised Statute (A.R.S.) § 36–2606 requires each medical practitioner licensed under Title 32 (i.e., doctor of medicine [MD], doctor of osteopathy [DO], doctor of dental surgery [DDS], doctor of dental medicine [DMD], doctor of pediatric medicine [DPM], homeopathic medical doctor [HMD], physician assistant [PA], nurse practitioner [NP], naturopathic doctor [ND], and doctor of optometry [OD]) and who possesses a Drug Enforcement Agency (DEA) license to review the preceding 12 months of a patient’s prescription monitoring program (PMP) record before prescribing an opioid analgesic or benzodiazepine-controlled substance listed in schedule II, III, or IV. Exceptions to reviewing a patient record are described in A.R.S. § 36–2606.
- Pharmacists employed by facilities with a valid U.S. DEA registration must register for the PMP online at https://arizona.pmpaware.net. Effective April 26, 2018, a dispensing pharmacist in an out-patient setting is required to review the preceding 12-month PMP record of a patient* receiving a Schedule II-controlled substance at the beginning of each new course of treatment.
  * Review of a PMP report is not required for veterinary dispensing.
- To register with the PMP, visit: https://arizona.pmpaware.net/.
- There is no fee to the prescriber or the pharmacist for PMP registration.

Additional Resources

- AZ PMPaware.net/login (AWARE) homepage link: https://arizona.pmpaware.net/login
- AZ PMP AWARE Website FAQ: https://arizona.pmpaware.net/support
- Prescriber Registration FAQ: https://pharmacypmp.az.gov/sites/default/files/Registration%20FAQs-Prescribers.pdf
- Dispensing Pharmacist Registration FAQ: https://pharmacypmp.az.gov/sites/default/files/Registration%20FAQs-Pharmacists.pdf
- Online PMP Training: https://pharmacypmp.az.gov/pmp-training

Contact Information

AZ PMP AWARE
https://pharmacypmp.az.gov
Arizona Board of Pharmacy
Phoenix, AZ
855.929.4767
pmp@azpharmacy.gov

This material was prepared by Health Services Advisory Group, the Medicare Quality Improvement Organization for Arizona, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. Publication No. AZ-11SOW-D.1-05062019-01
Crosswalk with MIPS-Improvement Activity Measure Category

If you are a Merit-based Incentive Payment System (MIPS)-eligible clinician and if you are reporting to the Arizona PMP, you may be eligible to report on the following Improvement Activities:

Annual registration in the PDMP

- **Activity ID:** IA_PSPA_5
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** Medium
- **Activity Description:** Annual registration by the MIPS-eligible clinician or group in the PDMP of the state where they practice is required. Activities that simply involve registration are insufficient. MIPS-eligible clinicians and groups must participate for a minimum of six months.
- **Suggested Documentation:**
  - Activation/Registration of an PDMP Account—Documentation evidencing activation/registration/continued participation in a PDMP account (e.g. an email) and,
  - Participation in PDMP—Evidence of participating in the PDMP, i.e., accessing/consulting (e.g. copies of patient reports created, with the personal health information [PHI] masked)

Consultation of the PDMP

- **Activity ID:** IA_PSPA_6
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** High
- **Activity Description:** Clinicians would attest to reviewing the patients' history of controlled substance prescription using state PDMP data prior to the issuance of a Controlled Substance Schedule II (CSII) opioid prescription lasting longer than three days. For the Quality Payment Program Year 2 (2018) and future years, clinicians would attest to a 75 percent review of applicable patient's history performance.
- **Suggested Documentation:**
  - Number of Issuances of CSII Prescription—Total number of issuances of a CSII prescription that lasts longer than three days over the same time period as those consulted; and
  - Documentation of Consulting the PDMP—Total number of patients for whom there is evidence of consulting the PDMP prior to issuing an CSII prescription (e.g. copies of patient reports created, with the PHI masked)

Completion of Training and Receipt of Approved Waiver for Provision of Opioid Medication-Assisted Treatments

- **Activity ID:** IA_PSPA_10
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** Medium
- **Activity Description:** Completion of training and obtaining an approved waiver for provision of medication-assisted treatment of opioid use disorders using buprenorphine.
- **Suggested Documentation:**
- Waiver—Substance Abuse and Mental Health Services Administration (SAMHSA) letter confirming waiver and physician-prescribing ID number; and
- Training—Certificate of completion of training to prescribe and dispense buprenorphine dated during the selected reporting period

**Centers for Disease Control and Prevention (CDC) Training on the CDC Guideline for Prescribing Opioids for Chronic Pain**

- **Activity ID:** IA_PSPA_22
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** High
- **Activity Description:** Completion of all modules from the CDC course "Applying CDC's Guideline for Prescribing Opioids" that reviews the 2016 "Guideline for Prescribing Opioids for Chronic Pain." Note: This activity may be selected once every four years to avoid duplicative information, given that some of the modules may change on a year-by-year basis. However, in four years, there would be a reasonable expectation for the set of modules to have undergone substantive change for the Improvement Activities performance category score.
- **Suggested Documentation:** Proof of “Completion of all the modules of the CDC course.”

**Patient Medication Risk Education**

- **Activity ID:** IA_PSPA_31
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** High
- **Activity Description:** In order to receive credit for this activity, MIPS-eligible clinicians must provide both written and verbal education regarding the risks of concurrent opioid and benzodiazepine use for patients who are prescribed both benzodiazepines and opioids. Education must be completed for at least 75 percent of qualifying patients and occur: (1) at the time of initial co-prescribing, and again following greater than six months of co-prescribing of benzodiazepines and opioids, or (2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.
- **Suggested Documentation:** Education must be completed for at least 75 percent of qualifying patients and occur as follows:
  1) at the time of initial co-prescribing, and again following greater than six months of co-prescribing of benzodiazepines and opioids, or
  2) at least once per MIPS performance period for patients taking concurrent opioid and benzodiazepine therapy.

**Use of CDC Guideline for Clinical Decision Support to Prescribe Opioids for Chronic Pain via Clinical Decision Support (new measure for 2019)**

- **Activity ID:** IA_PSPA_32
- **Subcategory:** Patient Safety & Practice Assessment
- **Activity Weight:** High
• **Activity Description:** In order to receive credit for this activity, MIPS-eligible clinicians must use the CDC Guideline for Prescribing Opioids for Chronic Pain via clinical decision support (CDS). For CDS to be most effective, it needs to be built directly into the clinician workflow and support decision making on a specific patient at the point of care. Specific examples of how the guideline could be incorporated into a CDS workflow include, but are not limited to, electronic health record (EHR)-based prescribing prompts, order sets that require review of guidelines before prescriptions can be entered, and prompts requiring review of guidelines before a subsequent action can be taken in the record.

• **Suggested Documentation:**
  - Eligible clinicians or groups using CDS must build the capability directly into the clinician workflow and document the decision-making support given to patients during the 90-day or year-long attestation period at the point of care; and
  - Document specific examples of how the guideline is incorporated into a CDS workflow. This may include, but is not limited to, EHR-based prescribing prompts, order sets that require review of guidelines before prescriptions can be entered, and prompts requiring review of guidelines before a subsequent action can be taken in the record.

**Technical Assistance for MIPS from HSAG**

[Contact Information]

Call Us 844.472.4227
Email Us HSAGQPPSupport@hsag.com
Visit Online www.hsag.com/QPP